Article

Accelerated Biological Aging from Breast Cancer Treatment May Lead to Cognitive Dysfunction

Study examines whether markers of biological aging due to cancer treatment are related to cognitive function in survivors of breast cancer.

Declining cognitive function in patients who had previously undergone breast cancer treatment may be associated with the aging-like effect of certain cancer treatments, according to a new study published in CANCER.

The researchers aimed to identify the relevance of indicators of biological aging to cognitive function in survivors of breast cancer.

Toxicities associated with cancer treatments can have long-term adverse effects on patients, increasing risks of persistent fatigue, pain, and cognitive dysfunction. Certain treatments can also contribute to accelerated biological aging due to its damaging effect on normal healthy cells in the body.

For the study, the authors evaluated 94 women aged 36 to 69 years who had been treated for early-stage breast cancer 3 to 6 years earlier. They examined indicators of biological aging, including elevated levels of DNA damage, reduced telomerase enzymatic activity, and shorter peripheral blood mononuclear cell (PBMC) telomere length, in relation to cognitive function.

According to the study’s findings, women previously treated for breast cancer who had both higher DNA damage and lower telomerase activity had lower executive function scores. Additionally, lower telomerase activity was linked to worse attention and motor speed scores, but telomerase length was not related to any of the neurocognitive domains.

Overall, the findings highlight a significant association between indicators of biological aging and cognitive performance in women who had been treated for breast cancer.

“These findings are important because they provide further information about what might be happening after cancer treatment that impacts cognitive decline in some individuals,” Judith E Carroll, PhD, associate professor of psychiatry, of the UCLA Cousins Center for Psychoneuroimmunology and the Semel Institute for Neuroscience and Human Behavior, said in a statement. “This information can inform future research and may lead to new interventions to prevent these cognitive declines.”

Reference

Cancer Treatments May Affect Cognitive Function By Accelerating Biological Aging [news release]. Wiley’s website. https://newsroom.wiley.com/press-release/cancer/cancer-treatments-may-affect-cognitive-function-accelerating-biological-aging. Accessed November 26, 2018.

Carroll JE, Van Dyk K, Bower JE. Cognitive performance in survivors of breast cancer and markers of biological aging. Cancer. 2018. https://doi.org/10.1002/cncr.31777

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards